The Evaluation of Banana Flower Stamens Extract on Prevention of Benign Prostatic Hyperplasia in Adults

Launched by TCI CO., LTD. · Feb 10, 2020

Keywords

ClinConnect Summary

**Trial Summary:**

This clinical trial is studying the effects of an extract from banana flower stamens to see if it can help prevent a condition called Benign Prostatic Hyperplasia (BPH) in adult men. BPH is a common issue as men age, causing the prostate gland to enlarge and leading to problems with urination. The researchers want to find out if this natural extract can improve symptoms or prevent BPH from getting worse.

To participate in the trial, men aged between 40 and 80 years who have mild to moderate urinary symptoms related to BPH are eligible. Participants will need to be in generally good health, without a recent history of cancer or certain other serious health issues. They should not have taken certain medications for BPH in the past few months. Those who join the study can expect to provide some information through questionnaires and may receive the banana flower extract or a placebo (a non-active treatment) as part of the study. It's important for potential participants to read and understand the study information and to give their consent before taking part. This trial is currently looking for volunteers, so there's an opportunity to contribute to research that may help others in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Male aged 40-80 years old
• • 2. 7 ≤ IPSS score \<19
• • 3. The subject did not take α-blocker or anticholinergic agents in the last 8 weeks. The subject did not take 5α-reductase inhibitor or androgen suppression agents in the last 16 weeks (depending on medical history).
• • 4. The subject isn't diagnosed with cancer
• • 5. The subject is able to read and finish the information on the questionnaire.
• • 6. The subject must read and sign the informed consent form after the study has been fully explained.
• Exclusion criteria:
• • 1. The subject has a history of epilepsy or convulsions, liver and kidney disease, cancer, endocrine disease, mental illness, alcohol or drug abuse, and other major organic diseases (depending on medical history).
• • 2. The lower urinary tract urination symptoms of the subject are not related to prostatic hypertrophy (depending on medical history).
• • 3. Residual urine volume \> 250 mL (depending on medical history)
• • 4. Subjects have had pelvic radiation therapy or pelvic surgery (including prostate or bladder surgery, but those who only have had a prostate slice can participate in the trial).
• • 5. Subjects have taken sexual hormone preparations including LHRH agonists, anti-androgens, feminine, or Penta-reductase inhibitors (Proscar and Avodart) 16 weeks prior to the trial.
• • 6. Subjects have participated in other clinical trials 12 weeks prior to the trial.